Table 2.
Comparison of uCrCl and eGFR data at cisplatin initiation, before each cisplatin cycle, and its change during therapy. Reported results are medians [25th–75th percentile], ranges [5th–95th percentile], and changes in kidney function over time during therapy (in ml/min/1.73m2/month. Changes were estimated with a linear mixed model taking into account the clustered nature of the data (Stata routine mixed).
| Variable | eGFR (CKD-EPI, ml/min/1.73m2) | Urinary Creatinine Clearance (uCrCl, ml/min/1.73m2) |
|---|---|---|
| At Cisplatin initiation (n = 121) | ||
|
Kidney function (median [25th–75th percentile] |
94 [82–106] | 102 [84–119] |
|
Kidney function (range [5th–95th percentile]) |
43–135 [62–121] | 40–303 [57–155] |
| Before each cycle (n = 480) | ||
|
Kidney function (median [25th–75th percentile] |
95 [85–105] | 104 [87–124] |
|
Kidney function (range [5th–95th percentile]) |
43–189 [67–124] | 13–417 [61–165] |
| Change during therapy | ||
| in ml/min/1.73m2/month (95%CI, p) |
− 0.1 (− 0.5–0.3, p = 0.568) |
− 0.5 (− 1.8–0.8, p = 0.425) |
eGFR estimated glomerular filtration rate, CKD-EPI chronic kidney disease epidemiology collaboration equation, uCrCl urinary creatinine clearance, 95% CI 95% confidence interval, p Wald test p value.